Mesoblast Limited: FIRST PATIENTS DOSED IN PHASE 2/3 RANDOMIZED CONTROLLED TRIAL OF MESOBLAST’S REMESTEMCEL-L FOR COVID-19 ACUTE RESPIRATORY DISTRESS SYNDROME

Press/Media

Period7 May 2020

Media coverage

1

Media coverage

  • TitleMesoblast Limited: FIRST PATIENTS DOSED IN PHASE 2/3 RANDOMIZED CONTROLLED TRIAL OF MESOBLAST’S REMESTEMCEL-L FOR COVID-19 ACUTE RESPIRATORY DISTRESS SYNDROME
    Media name/outletImpact Financial News
    Country/TerritoryUnited Kingdom
    Date7/05/20
    PersonsAlan Moskowitz, Emilia Bagiella, Annetine Gelijns
View all 1
View less